Melanóma: vizsgálatok itt: Lengyelország
16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 1/2. fázisNot yet taking people in LengyelországA Phase I/II trial to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JJP-1008 Alone or in Combination in Participants with Advanced Melanoma and Other Solid Tumors
- Where
- Gdansk, Skorzewo, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 30
- Run by
- JJP BIOLOGICS Sp. z o.o.
See details and how to join2026-527193-36-00 · EU 2026-527193-36-00 - 2. fázisTaking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Cracow
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Cracow, Lodz, Rzeszów, Siedlce, Skorzewo
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 2/3. fázisTaking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Gdansk, Gliwice, Konin, Siedlce, Warsaw
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - 3. fázisTaking peopleStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Where
- Lublin, Warsaw
- Életkor
- 18 év to 70 év
- People
- 670 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00 - 3. fázisTaking peopleVO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- Where
- Cracow, Gdansk, Warsaw
- Életkor
- 12 év and over
- People
- 400 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00 - 3. fázisTaking peopleAdjuvant Tebentafusp in High Risk Ocular Melanoma
- Where
- Warsaw
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT06246149 · EU 2023-510333-28-00 - 3. fázisTaking peopleRandomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
- Where
- Gdansk
- Életkor
- 18 év and over
- People
- 119 worldwide
- Run by
- Mabxience Research S.L.
See details and how to join2025-521562-95-00 · EU 2025-521562-95-00 - 3. fázisTaking peopleNeoadjuvant Darovasertib in Primary Uveal Melanoma
- Where
- Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00 - 1. fázisTaking peopleA Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
- Where
- Gdansk
- Életkor
- 18 év and over
- People
- 83 worldwide
- Run by
- Celltrion Inc.
See details and how to join2023-510017-26-00 · EU 2023-510017-26-00 - 2/3. fázisTaking peopleA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Where
- Warsaw
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06581406 · EU 2023-508784-68-00 - 3. fázisTaking peopleTebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Where
- Bydgoszcz, Gdansk, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT05549297 · EU 2022-502732-39-00 - 3. fázisTaking peopleIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Where
- Bydgoszcz, Gdansk, Skorzewo, Warsaw
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Immunocore Ltd
See details and how to joinNCT06112314 - No phaseNot yet taking people in LengyelországImpact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence
- Where
- Warsaw
- Életkor
- 18 év and over
- People
- 400
- Run by
- Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
See details and how to joinNCT07361666 - 4. fázisTaking peopleA Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- Where
- Cracow, Gdansk, Warsaw
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Replimune, Inc.
See details and how to joinNCT06887348 · EU 2025-521621-33-00 - No phaseTaking peopleStereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Where
- Gdansk, Warsaw
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04498767